Home Business Dr Reddy’s launches Remdesivir to deal with Covid-19 in India | India...

Dr Reddy’s launches Remdesivir to deal with Covid-19 in India | India Information

SHARE


HYDERABAD: Pharma major Dr Reddy’s Laboratories Ltd on Wednesday introduced the rollout of potential Covid-19 therapy generic drug Remdesivir, beneath the Redyx brand name in India. Dr Reddy’s has introduced the launch of Redyx at Rs 5400 per 100 mg vial.
The launch follows the non-exclusive settlement that Dr Reddy’s entered into with Remdesivir’s innovator firm Gilead Sciences Inc of US in June this 12 months to register, manufacture and promote Remdesivir in 127 international locations together with India.
Remdesivir, which was initially developed for the therapy of Ebola by Gilead, has been authorised by India’s drug regulator Drug Controller Basic of India (DCGI) for restricted emergency use for the therapy of Covid-19 sufferers hospitalized with extreme signs.
M V Ramana, CEO, Branded Markets (India and Rising Markets), Dr Reddy’s Laboratories, mentioned “We are going to proceed our efforts to develop merchandise that tackle important unmet wants of sufferers. The launch of Redyx reaffirms our dedication to bringing in essential medication for sufferers affected by Covid-19 in India.”
Other than Remdesivir, Dr Reddy’s has already launched final month one other Covid-19 therapy anti-viral drug Favipiravir 200 mg beneath its innovator brand Avigan within the Indian market following a pact with its innovator Fujifilm of Japan. Favipiravir has been authorised by DCGI for the therapy of Covid-19 sufferers affected by gentle to average signs.

LEAVE A REPLY

Please enter your comment!
Please enter your name here